Ignite Creation Date:
2025-12-24 @ 2:17 PM
Ignite Modification Date:
2026-02-21 @ 6:45 PM
Study NCT ID:
NCT05856695
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-24
First Post:
2023-05-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-11-17
Start Date Type:
ACTUAL
Primary Completion Date:
2026-02
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-02
Completion Date Type:
ESTIMATED
First Submit Date:
2023-05-04
First Submit QC Date:
None
Study First Post Date:
2023-05-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-19
Last Update Post Date:
2025-09-24
Last Update Post Date Type:
ESTIMATED